{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:21:16Z","timestamp":1780370476290,"version":"3.54.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.rdc.2013.05.004","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T16:31:30Z","timestamp":1373041890000},"page":"751-766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of Juvenile Idiopathic Arthritis in the Biologic Age"],"prefix":"10.1016","volume":"39","author":[{"given":"Matthew L.","family":"Stoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy Q.","family":"Cron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2013.05.004_bib1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.20945","article-title":"Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease","volume":"52","author":"Ravelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1546-0096-10-29","article-title":"Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis","volume":"10","author":"Tebo","year":"2012","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2013.05.004_bib4","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1002\/art.22173","article-title":"Patients with juvenile psoriatic arthritis comprise two distinct populations","volume":"54","author":"Stoll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib5","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3899\/jrheum.100014","article-title":"Spondyloarthritis in a pediatric population: risk factors for sacroiliitis","volume":"37","author":"Stoll","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.rdc.2013.05.004_bib7","first-page":"343","article-title":"Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR)","volume":"35","author":"Behrens","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(08)60999-X","article-title":"Are withdrawal trials in paediatric rheumatic disease helpful?","volume":"372","author":"Lehman","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2013.05.004_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2013.05.004_bib11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/annrheumdis-2012-201844","article-title":"NSAIDs and radiographic progression in ankylosing spondylitis. Bagging big game with small arms?","volume":"71","author":"Haroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2013.05.004_bib12","first-page":"37","article-title":"Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: safety, efficacy, and features affecting outcome. A comprehensive review of the literature","volume":"1","author":"Gotte","year":"2009","journal-title":"Open Access Rheumatol Res Rev"},{"key":"10.1016\/j.rdc.2013.05.004_bib13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/rheumatology\/keh313","article-title":"Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial","volume":"43","author":"Zulian","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2013.05.004_bib14","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3899\/jrheum.111441","article-title":"Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis","volume":"39","author":"Stoll","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib15","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3899\/jrheum.120110","article-title":"Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry","volume":"39","author":"Beukelman","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2431-12-29","article-title":"Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis","volume":"12","author":"Kemper","year":"2012","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.rdc.2013.05.004_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00063030-200014030-00003","article-title":"Comparative tolerability of treatments for juvenile idiopathic arthritis","volume":"14","author":"Prieur","year":"2000","journal-title":"BioDrugs"},{"key":"10.1016\/j.rdc.2013.05.004_bib18","first-page":"845","article-title":"Sulfasalazine for the management of juvenile rheumatoid arthritis","volume":"28","author":"Brooks","year":"2001","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib19","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2013.05.004_bib20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2165\/00003495-199958060-00010","article-title":"Leflunomide: a review of its use in active rheumatoid arthritis","volume":"58","author":"Prakash","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.rdc.2013.05.004_bib21","doi-asserted-by":"crossref","first-page":"SR35","DOI":"10.12659\/MSM.882109","article-title":"Etanercept treatment in juvenile idiopathic arthritis: the Polish registry","volume":"17","author":"Zuber","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.rdc.2013.05.004_bib22","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/ker103","article-title":"Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry","volume":"50","author":"Sevcic","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2013.05.004_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2013.05.004_bib24","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2013.05.004_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A\u00a0randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib27","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A\u00a0randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2013.05.004_bib29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2013.05.004_bib30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2013.05.004_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A\u00a0multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2013.05.004_bib33","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2013.05.004_bib34","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2013.05.004_bib35","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib36","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2013.05.004_bib37","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2013.05.004_bib38","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2013.05.004_bib39","first-page":"S682","article-title":"Efficacy of safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial","volume":"64","author":"Brunner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0002-9343(99)80109-0","article-title":"Biological therapies: a novel approach to the treatment of autoimmune disease","volume":"99","author":"Fox","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2013.05.004_bib41","first-page":"229","article-title":"Biological therapies for the treatment of juvenile idiopathic arthritis: lessons from the adult and pediatric experiences","volume":"2","author":"Stoll","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.rdc.2013.05.004_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","article-title":"Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients","volume":"50","author":"Southwood","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2013.05.004_bib43","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib44","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/erp.10.13","article-title":"Patient outcomes after anti TNF-alpha drugs for Crohn's disease","volume":"10","author":"Assasi","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.rdc.2013.05.004_bib46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry","volume":"68","author":"Horneff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2013.05.004_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03009742.2010.517546","article-title":"Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis","volume":"40","author":"Trachana","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib48","doi-asserted-by":"crossref","first-page":"765380","DOI":"10.5402\/2012\/765380","article-title":"High dose infliximab in the treatment of refractory uveitis: does dose matter?","volume":"2012","author":"Sukumaran","year":"2012","journal-title":"ISRN Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib49","unstructured":"Tambralli A, Beukelman T, Weiser P, et\u00a0al. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol, in press."},{"key":"10.1016\/j.rdc.2013.05.004_bib50","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/art.21121","article-title":"Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy","volume":"52","author":"Tse","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/BOR.0b013e328348b278","article-title":"Psoriatic juvenile idiopathic arthritis: a tale of two subgroups","volume":"23","author":"Stoll","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib52","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1546-0096-8-23","article-title":"Guilt by association\u2014what is the true risk of malignancy in children treated with etanercept for JIA?","volume":"8","author":"Cron","year":"2010","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2013.05.004_bib54","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib55","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib56","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.rdc.2013.05.004_bib57","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3899\/jrheum.100726","article-title":"Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series","volume":"38","author":"Record","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2013.05.004_bib60","article-title":"Anakinra for rheumatoid arthritis","author":"Mertens","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rdc.2013.05.004_bib61","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/art.21206","article-title":"A\u00a0signal achievement in the treatment of arthritis","volume":"52","author":"Cron","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib62","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","article-title":"Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis","volume":"249","author":"Kenawy","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.rdc.2013.05.004_bib63","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar2984","article-title":"Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment","volume":"12","author":"Simon","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.rdc.2013.05.004_bib64","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rdc.2013.05.004_bib65","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1248\/bpb.30.2001","article-title":"Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases","volume":"30","author":"Ohsugi","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.rdc.2013.05.004_bib66","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/ard.2010.145359","article-title":"Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment","volume":"70","author":"Inaba","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 6","key":"10.1016\/j.rdc.2013.05.004_bib67","doi-asserted-by":"crossref","first-page":"vi37","DOI":"10.1093\/rheumatology\/kes283","article-title":"Overview of safety of non-biologic and biologic DMARDs","volume":"51","author":"Ruderman","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2013.05.004_bib68","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"Woo","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2013.05.004_bib69","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-Lopez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.rdc.2013.05.004_bib70","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2013.05.004_bib71","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2013.05.004_bib72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.rdc.2013.05.004_bib73","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2013.05.004_bib74","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: a systematic review","volume":"51","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2013.05.004_bib75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0950-3579(98)80018-6","article-title":"Systemic onset juvenile rheumatoid arthritis","volume":"12","author":"Schneider","year":"1998","journal-title":"Baillieres Clin Rheumatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X13000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X13000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:12:26Z","timestamp":1760181146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X13000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0889857X13000665"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2013.05.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Juvenile Idiopathic Arthritis in the Biologic Age","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2013.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}